Navigation Links
Lithium of No Benefit in ALS, Study Finds
Date:8/11/2010

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Aug. 11 (HealthDay News) -- A new study appears to dash hopes that the psychiatric drug lithium can benefit patients with amyotrophic lateral sclerosis (ALS).

The investigation involving 171 people with ALS was stopped early, in November 2009, because of high dropout rates from death, side effects or because patients thought the drug was ineffective.

ALS -- sometimes called Lou Gehrig's disease after the N.Y. Yankee who died of the condition -- is a progressive nervous system disorder that causes weakness in muscles, including those controlling breathing and swallowing. Median survival is three years, and only one drug -- riluzole -- is approved for ALS treatment in the United States.

Interest in lithium, which is often used to treat bipolar disorder, increased after a small Italian study was published two years ago, suggesting a beneficial effect for ALS patients, said Dr. Adriano Chio, an associate professor of neurology at the University of Torino, Italy. In that study, lithium was thought to have prolonged survival of 16 ALS patients, Chio said.

How might lithium have helped?

"Lithium could have an effect on one of the mechanisms supposedly related to the motor neuron degeneration in ALS, the accumulation of pathological proteins in the neuron," said Chio, who led the new study, noting subsequent research has not confirmed this effect.

In the new study, published in the Aug. 17 issue of Neurology, the drop-out rate, at 68 percent, was two times higher than the drop-out rate reported by previous trials, Chio said.

All participants received lithium, but in two different doses, and the drug was not well-tolerated by either group. Patients died or lost their autonomy at the same rate in both groups.

In an editorial accompanying the study, Dr. Carmel Armon of Tufts University said one limitation of the Chio study, which Chio acknowledges, is that it didn't use a true placebo, but rather different doses. Other ongoing studies that are comparing the active drug to placebo may give the definitive answers, Armon said.

"This study [by Chio] shows there are toxic doses of lithium," said Lucie Bruijn, chief scientist for the ALS Association in Washington, D.C.

"We knew lithium has to be monitored carefully in terms of dose," Bruijn said. "What's shown here [in the new study] is a toxic level in some cases and not a strong benefit."

Even at what was termed "subtherapeutic doses," the lithium was poorly tolerated, Chio found. All 71 patients reported at least one adverse event, some as serious as heart disturbance, cerebral hemorrhage or deep vein blood clots.

Chio said two other trials are assessing the effect of lithium in ALS, but he doubts any positive effect of lithium will be shown.

In the future, Chio added, stem cell therapy may prove useful for ALS.

More information

To learn more about ALS, visit the ALS Association.

SOURCES: Adriano Chio, M.D., associate professor, neurology, First Faculty of Medicine, University of Torino, Italy; Lucie Bruijn, Ph.D., chief scientist, ALS Association, Washington, D.C.; Aug. 17, 2010, Neurology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. No Evidence That Lithium Helps in ALS
2. 30 million women to benefit from health reform law
3. Researchers study benefits of white button mushrooms
4. Study finds patients benefit from thorough discussion of recommended operations
5. Society of Interventional Radiology advances global definition of specialty, benefits patients
6. Social Security Disability Benefits Can Be Crucial to Surviving With Spinal Cord Injury, Allsup Reports
7. Advocate Health Care Reports $462 Million in Community Benefits
8. Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities
9. Mulago Positive Women's Network Announce Their "BONO" Bracelet Fundraiser to Benefit HIV+ Women in Uganda
10. Intensively lowering glucose: Possible benefits must be weighed against risks
11. Examining risks and benefits of alcohol consumption
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lithium of No Benefit in ALS, Study Finds
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
(Date:11/30/2016)... Wisconsin (PRWEB) , ... November 30, 2016 , ... ... in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of the ... year on the list, having ranked from 2008-2016. In addition, Standard Process was ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... and mental health treatment has announced the opening of a new residential mental ... for girls with mental health issues such as severe anxiety, depression, bi-polar disorder, ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... stylish design wanted by today’s consumers at an affordable price, is now available ... the new watch is “a game changer” when it comes to the smartwatch. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2016  The Addiction Treatment Advisory Group (ATAG), ... Care Pharmacy (AMCP), has released detailed findings on ... opioid addiction crisis, including through improved access to ... ATAG,s newly released paper, "The Role of Managed ... many issues around gaps and barriers to addiction ...
(Date:12/2/2016)... 2, 2016 Boston Scientific Corporation (NYSE: ... acquire certain manufacturing assets and capabilities of the Neovasc, ... biological tissue business, as well as a 15% equity ... in cash. The Neovasc advanced biological tissue business makes ... Scientific Lotus™ Valve System. * Upon completion of ...
Breaking Medicine Technology: